Elocom (mometasone furoate) lotion 30 ml.


Manufacturer: Belgium

Inflammatory phenomena and itching in dermatoses amenable to corticosteroid therapy, including psoriasis (except for common plaque psoriasis) and atopic dermatitis, in adults and children aged 2 yEars and Nose and older.



Elocom lotion Storage
active substance: mometasone furoate;

1 g of cream contains mometasone furoate 1 mg;

Elocom lotion Excipients: hexylene glycol, purified water, concentrated phosphoric acid, hydrogenated phosphotidylcholine, titanium dioxide (E 171), aluminum salt of octenyl succinate starch, white wax, white soft paraffin.

Elocom lotion Dosage form

Main physical and chemical properties: white or almost white color of soft consistency, homogeneous cream, without foreign inclusions.

Pharmacotherapeutic group
Corticosteroids for use in dermatology.

ATX code D07A C13.

Pharmacological properties


Mometasone furoate is a synthetic glucocorticosteroid for topical use with anti-inflammatory, antipruritic and antiexudative effects.


Pharmacokinetic studies have shown that systemic absorption after topical application of mometasone furoate 0.1% is minimal; approximately 0.4% of the administered dose is eliminated from the body within 72 hours after application. It was almost impossible to establish the nature of the metabolites due to the small amount present in blood plasma and secretions.

Inflammatory phenomena and itching in dermatoses treated with corticosteroids, including psoriasis (except for common plaque psoriasis) and atopic dermatitis, in adults and children over 2 years of age.

Elocom® is contraindicated in rosacea, acne vulgaris, skin atrophy, perioral dermatitis, perianal and genital itching, diaper rash, bacterial (eg impetigo, pyoderma), viral (eg herpes simplex, herpes zoster, shingles and shingles) mollusk), parasitic and fungal (eg candida or dermatophyte) infections, tuberculosis, syphilis or post-vaccination reactions. Elocom® should not be applied to wounds or ulcerated skin. The drug is contraindicated in patients with hypersensitivity to any of the components of the drug or to other glucocorticosteroids.

Interaction with other medicinal products and other forms of interaction
Not installed.

Features of application
In case of irritation or sensitization, Elocom® treatment should be discontinued and appropriate treatment instituted.

In case of concomitant skin infection, an appropriate antifungal or antibacterial drug should be used. If positive dynamics cannot be achieved within a short time, Elocom® cream should be discontinued until the infection is completely eliminated.

Systemic topical administration of various glucocorticosteroids (GCS) may cause reversible suppression of hypothalamic-pituitary-adrenal function with possible glucocorticosteroid insufficiency after discontinuation of treatment. Some patients may experience Cushing’s syndrome, hyperglycemia, and glucosuria.

Patients using topical steroids on large areas of skin or using occlusive dressings should be periodically tested for suppression of hypothalamic-pituitary-adrenal function. This test can be performed by performing an ACTH stimulation test, measuring morning plasma cortisol levels and in media other than urine.